Moreover, in 2023, the Focused Update on the above-mentioned guidelines was released, and recent studies have shown that SGLT-2 inhibitors can reduce the risk of HF hospitalizations and CV death in patients with both HFpEF or HFmrEF [15]. This evidence concerns the gene SLC5A2 and hydrops fetalis.